ArticleNature medicine2020
Publisher Correction: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.
Open access · bronzeAbstract readPublished Erratum
In one paragraph
Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics.Journal of translational medicine · 2022Review
- Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.Frontiers in immunology · 2022Review
- Application of CRISPR/Cas9 in Alzheimer's Disease.Frontiers in neuroscience · 2021Review
Corrections and comments
- Erratum for
Authors and funding
38 authors at 5 institutions in 3 countries.
You Lu *Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China. radyoulu@hotmail.com.ORCID http://orcid.org/0000-0003-1671-1408
Jianxin Xue *Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Tao Deng *Chengdu MedGenCell, Co., Ltd, Chengdu, China.
Xiaojuan Zhou *Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Kun Yu *Chengdu MedGenCell, Co., Ltd, Chengdu, China.
Lei DengJacobi Medical Center, NYC Health Hospitals, Albert Einstein College of Medicine, New York, NY, USA.
Meijuan HuangDepartment of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Xin YiGeneplus-Beijing Institute, Beijing, China.
Maozhi LiangCenter of GCP, West China Hospital, Sichuan University, Chengdu, China.
Yu WangZenRhyme Consulting Service, Ltd, Shanghai, China.
Haige ShenZenRhyme Consulting Service, Ltd, Shanghai, China.
Ruizhan TongDepartment of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Wenbo WangNational Research Center for Translational Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Li LiDepartment of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Jin SongGeneplus-Beijing Institute, Beijing, China.
Jing LiGeneplus-Beijing Institute, Beijing, China.
Xiaoxing SuBerry Oncology Co. Ltd, Fujian, China.
Zhenyu DingDepartment of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Youling GongDepartment of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Jiang ZhuDepartment of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Yongsheng WangDepartment of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Bingwen ZouDepartment of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Yan ZhangDepartment of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Yanying LiDepartment of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Lin ZhouDepartment of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Yongmei LiuDepartment of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Min YuDepartment of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Yuqi WangGeneplus-Beijing Institute, Beijing, China.
Xuanwei ZhangDepartment of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Limei YinDepartment of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Xuefeng XiaGeneplus-Beijing Institute, Beijing, China.
Yong ZengChengdu MedGenCell, Co., Ltd, Chengdu, China.
Qiao ZhouDepartment of Pathology, West China Hospital, Sichuan University, Chengdu, China.
Binwu YingDepartment of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.
Chong ChenState Key Laboratory of Biotherapy and Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Yuquan WeiState Key Laboratory of Biotherapy and Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Weimin LiDepartment of Respiratory and Critical Care Medicine and Frontier Science Center of Disease Molecular Network, West China Hospital, Sichuan University, Chengdu, China.
Tony MokState Key Laboratory of Translational Oncology, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, China.
Sichuan University · CNBerry Oncology (China) · CNChinese University of Hong Kong · HKJacobi Medical Center · USShanghai Jiao Tong University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.